Following on from information provided to NICE by the company in May 2018, the appraisal of Atrasentan for hormone refractory prostate cancer [ID390] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 390 |
| Referral date | 01 June 2004 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in May 2018, the appraisal of Atrasentan for hormone refractory prostate cancer [ID390] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 27 May 2005 | Topic summary published |
| 25 August 2006 | This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme. |
| 8 January 2007 | Topic is suspended as the manufacturer has not applied for EMEA regulatory approval at this time |
For further information on our processes and methods, please see our CHTE processes and methods manual